Clinical Indications for DXA Scan
Based on the Irish Osteoporosis Guidelines for Health Professionals and The American College of Radiology 2008
Contraindications (reasons against) for performing DXA:
Recently had gastrointestinal contrast or radionuclides
Severe degenerative changes or fracture deformity in the measurement area
Inability to attain the correct position and/or remain motionless for the
Extreme obesity or extremely low body mass index that may inversely affect the
technique and the ability to obtain accurate and precise measurements
Criteria for having a DXA scan
Group 1:
All women 65 years of age and older All men age 70 years and older (asymptomatic screening)
Women under age 65 with additional risk for osteoporosis.
o Women discontinuing oestrogen or oestrogen deficiency (peri-
o Early or premature menopause (before age 45 years old) o History of amenorrhoea (no periods) for more than 1 year under the
o History of maternal hip fracture that occurred after the age of 50 years
o Eating disorders (current/past) o Men younger than 70 with hypogonadism/ testosterone deficiency o Adults of any age with fragility fractures o Men or women receiving or expected to receive steroid treatment for
more than 3months (e.g. >5mg Prednisolone for more than 3 months in a year)
o Individuals beginning or receiving long-term therapy with medication
known to adversely affect bone mineral density:
Anti- coagulants - warfarin, heparin Anti-epileptics - Epinutin Aromatase inhibitors etc (refer to next page for list of
medications that may cause osteoporosis)
o Individuals of any age with radiologic evidence of:
low bone mass (osteopenia), vertebral deformity (kyphosis) the presence of vertebral compression fractures.
o Men and women any age with a disease associated with defect in bone
development, low bone mass or bone loss such as:
osteogenesis imperfect Hyperthyroidism (overactive thyroid gland) inflammatory bowel disease (IBD). Rheumatoid arthritis growth hormone deficiency
o Men and women of any age who have the following risk factors;
have experienced a loss of height by more than 2cm have had a low BMI (less than 18kg/m2) have experienced severe malnutrition or poor nutrition have an excessive alcohol intake (>14 units a week for women
have been or currently are smokers have a history of taking excessive exercise, particularly with
Chemotherapy Radiation Thyroxine (Eltroxin), if serum levels are high Anticonvulsant therapy or anti- epileptic medications (phenytoin and
phenobarbitone)- interfere with calcium absorption and production of Vit. D.
Chronic heparin or Warfarin therapy Long term lithium therapy GnRh analogues LHRH analogues; testosterone suppression Prolactin raising drugs such as antipsychotic medications e.g. some SSRI, Aromatase inhibitors for the treatment of Prostatic and Breast Cancers e.g.
Diuretics such as Burinex and Lasix (ferusemide) Proton Pump Inhibitors
VIEW ONLY PCSK9 mAbs or even vaccines – the new statins? LONDON, UK----18th March 2013----ExpertREACT. Novel PCSK9 (proprotein convertases subtilisin/kexin type 9) inhibitors, such as Sanofi’s anti-PCSK9 monoclonal antibody SAR236553, have impressive LDL-C reducing efficacy. PCSK9 vaccines may represent an alternative strategy to the monoclonal antibody approach, taking
LIKABEHANDLINGSPLAN INNEHÅLL Vår värdegrund kränkande behandling VÅR VÄRDEGRUND Alla människor är födda fria och lika i värde och rättigheter. De är utrustade med förnuft och samvete och bör handla gentemot varandra i en anda av broderskap. (FN:s deklaration om de mänskliga rättigheterna) Glimåkra folkhögskolas måldokument beskriver arbetet här uti